Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects with Type 2 Diabetes Mellitus

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Phenomix
• Collaborator: Forest Laboratories

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus, drug naïve or willing to wash-out from existing oral therapy

• BMI 25 to 48 kg/m2, inclusive

• HbA1c 7.0% - 10.0%, inclusive

• Age 18 to 75 years, inclusive

Exclusion Criteria:

• Currently on 3 or more oral antidiabetic drugs or insulin.

• Type 1 diabetes mellitus